Completed PHASE1 INTERVENTIONAL 2-arm NCT00688090

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

A Phase 1/2, Open Label, Non-Randomized Dose Escalation Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma

Sponsor: Mannkind Corporation

Conditions Advanced Melanoma Stage III and IV Melanoma

Interventions Biological: MKC1106-MT Biological: MKCC1106-MT

Updated 6 times since 2017 Last updated: Aug 2, 2010 Started: Jun 30, 2008 Primary completion: Dec 31, 2009 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Melanoma and Stage III and IV Melanoma, this trial is completed. The trial is conducted by Mannkind Corporation and has accumulated 6 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mannkind Corporation

Data source: Mannkind Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States
• Tampa, United States